Parag JhaveriFounder

United States - San Francisco, California

My passion and joy is in building business and products that improve human health, and in working closely with technical founders in building extraordinary companies. I have a track record for solid investments in early-stage companies and M&A transactions in deep tech life science and healthcare startups.

Parag is a high-energy, results-oriented, and high-performance Healthcare executive who empowers people, solves complex problems, builds new capabilities, and develops and executes the strategy. He brings multiple years of executive leadership experience of corporate, consulting, and early-stage healthcare venture capital experience. He has worked with clients globally in private equity, health systems (profit and nonprofit), providers, medical device/diagnostics, next-generation sequencing, specialty pharmaceuticals, biotech, biopharma, pharmacy benefits management providers, multi-specialty practice groups, digital health, and startups. His analytical expertise is underpinned by a solid technical foundation in engineering.

Parag has a MBA from Haas School of Business, UC Berkeley, after receiving a MS in Industrial Engineering from Louisiana Tech University.

Healthcare Exits:
Celgene acq by Bristol Myers Squibb (NYSE: BMY) $74B
Ortho Clinical Diagnostics acq by Carlyle $4B
Cole-Parmer acq by GTCR $2B+
intraFusion acq by McKesson (NYSE: MCK) $0.5B
Ottr acq by CareDx (NASDAQ: CDNA)
Combinati acq by Thermofisher (NYSE: TMO)
Fluent Bio acq by Illumina (NASDAQ:ILMN)

Active:
Codetta Bio
Cellsonics
Shadowbox

Technology related companies
Robinhood, IPO (NASDAQ: HOOD)
Phenom
Menlo Micro

Areas of distinctive expertise and experience include:
• Multiple full business developments / strategic partnerships / alliances (deal sheet available)
• Growth / Competitive Assessment / Strategy, New Product Development, Commercialization / Go-to-
Market strategy
• Business Operations, Finance
• End-to-end M&A, Commercial (CDD), Operational Due Diligence (ODD), Post-merger integration and
licensing deals ranging in value from $20M to $78B+ in EV (deal sheet available)
• Financial statement analysis and valuation modeling
• Data Analytics and Insights
• FDA regulated experience (RUO and IVD) - launched multiple applications (instrument, assays, software)
• Strong and extensive industry and investor network (US, India, Singapore), working with early-stage, late-
stage venture capital and private equity (PE) companies
• Early and Growth stage investor

US Citizen

Contact me: LinkedIn.